Right pricing to hold the key for Zydus Cadila’s vaccine launch, Health News, ET HealthWorld

The advice of the topic knowledgeable committee (SEC) for the grant of promoting authorisation for Bharat Biotech‘s Covaxin for 2-18-year-old youngsters has put the destiny of Zydus Cadila vaccine rollout in query, as the value of the vaccine appears to be holding up its induction in the vaccination programme.

Zydus Cadila has the drug regulator’s emergency use authorisation to administer its Covid vaccine, ZyCoV-D, in youngsters aged 12-18 years. As Covaxin is ready to develop into accessible for the identical age group as effectively, the bargaining place of the authorities will enhance, as negotiations are underway with Zydus concerning the value of the vaccine.

“While the authorities had mentioned that the Zydus vaccine will likely be added to the vaccination programme in October, negotiations are nonetheless not over,” mentioned a authorities official. An individual in the know mentioned Zydus Cadila has quoted lower than ₹300 for a single dose of its vaccine. However, this value does not embrace the value of the pharmaJet, which is required to administer the vaccine.

The pharmaJet, a needle-free applicator for painless intradermal vaccine supply, has been imported by Ahmedabad-based Zydus Cadila.

“It’s an expensive device and hence jacks up the overall price of the vaccine,” the authorities official mentioned. The pharmaJet penetrates the cell membrane. Each jet delivers a specific amount of the vaccine. So, a single dose is unfold into two pictures throughout two arms.

The jet injector can be utilized for administering round 20,000 doses.

The authorities has been shopping for Covaxin at ₹225 a dose and the different India-made Covid vaccine, Covishield, at ₹215.

Health secretary Rajesh Bhushan had earlier mentioned the value of the Zydus Cadila vaccine could be fairly totally different from the current vaccines.

Reference link